...
首页> 外文期刊>The Annals of Thoracic Surgery: Official Journal of the Society of Thoracic Surgeons and the Southern Thoracic Surgical Association >Excellent Outcomes With Use of Synthetic Vascular Grafts for Treatment of Mycotic Aortic Pseudoaneurysms After Heart Transplantation
【24h】

Excellent Outcomes With Use of Synthetic Vascular Grafts for Treatment of Mycotic Aortic Pseudoaneurysms After Heart Transplantation

机译:使用合成血管移植物治疗心脏移植后的真菌性主动脉假性动脉瘤的出色结果

获取原文

摘要

Mycotic pseudoaneurysm is a rare but potentially lethal complication after heart transplantation. Allograft has been advocated as the choice of material for aortic replacement. We report a series of 7 patients with pseudoaneurysm that was treated with primary repair or synthetic graft replacement.MethodsBetween October 2005 and February 2011, 8 patients (mean age, 55.3 years; range, 39 to 67 years), were diagnosed with mycotic pseudoaneurysms of the ascending aorta 2 to 29 months after transplantation. One patient declined operative repair, and the remainder had urgent or emergency surgical intervention. One patient had primary repair at the cardioplegia site, and one had primary end-to-end anastomosis after the infected recipient aortic segment was resected. Five patients had replacement of the infected aorta with a Dacron graft (DuPont, Wilmington, DE) for pseudoaneurysm development at the suture line or donor aorta. Clinical and radiologic follow-up assessments were performed in all patients.ResultsThere were no operative or in-hospital deaths. None of the patients had major postoperative complications, and there was no cardiac allograft dysfunction. Median follow-up was 25 months (range, 1 to 48 months). One patient died of a pulmonary embolism 10 months after the operation. The remaining 6 patients remain free of infection. The most recent radiologic follow-up showed no residual or recurrence of pseudoaneurysms among the surviving patients.ConclusionsA synthetic vascular graft to replace the infected aorta is a viable aortic substitute among transplant recipients, and in the presence of a vascularized flap, can offer excellent midterm outcomes.CTSNet classification:34Mycotic pseudoaneurysm, often with concurrent mediastinal abscess, is a relatively rare but potentially lethal complication after orthotopic heart transplantation. Only a small number of cases have been reported. Because of concern about placing synthetic material within an infected field in an immunosuppressed patient, allograft or xenograft material has generally been favored for aortic repair or replacement in this setting. Although a handful of reports have used a synthetic graft to replace the diseased aorta [
机译:真菌性假性动脉瘤是心脏移植术后罕见但潜在的致命并发症。提倡同种异体移植作为主动脉置换材料的选择。我们报告了7例经初次修复或人工合成置换治疗的假性动脉瘤患者的方法。方法在2005年10月至2011年2月之间,有8例患者(平均年龄55.3岁;范围39至67岁)被诊断为真菌性假性动脉瘤。移植后2至29个月升主动脉。一名患者拒绝手术修复,其余患者接受了紧急或紧急手术干预。一名患者在心脏停搏部位进行了一次初次修复,一名患者在切除了受感染的主动脉段后进行了初次端到端吻合。五名患者用Dacron移植物(杜邦,威尔明顿,DE)替换了受感染的主动脉,以在缝合线或供体主动脉上形成假性动脉瘤。所有患者均进行了临床和影像学随访评估。结果没有手术或住院死亡。所有患者均无重大术后并发症,也没有心脏同种异体移植功能障碍。中位随访时间为25个月(范围1至48个月)。术后10个月,一名患者死于肺栓塞。其余6名患者保持无感染。最新的放射学随访结果显示,幸存的患者中没有假性动脉瘤的残留或复发。结论人工血管替代人工血管感染是移植受者中可行的主动脉替代物,并且在有血管皮瓣的情况下,可以提供良好的中期妊娠CTSNet分类:34真菌性假性动脉瘤常伴有纵隔脓肿,是一种相对罕见但潜在致命的并发症,原位心脏移植术后。仅报告了少数病例。由于担心将合成材料放置在免疫抑制患者的感染区域内,因此在这种情况下,通常倾向于采用同种异体或异种材料进行主动脉修复或置换。尽管有少数报道使用合成的移植物来代替患病的主动脉[

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号